TABLE 5.
Medication and Motor Complications of Patients (N = 8) Before and After Treatment Along With Total Electrical Energy Delivered
| Baselinea | 6-mo follow-upb | 1-yr follow-up | |
|---|---|---|---|
| LEDD (mg) | 777.3 ± 264.1 | 535.9 ± 125.3 | 457.8 ± 112.0a |
| TEED (μW) | |||
| (STN) TEED | n/a | 100 ± 37 | 98 ± 33 |
| (GPi) TEED | n/a | 78 ± 28 | 106 ± 32 |
| UPDRS IV | |||
| Total | 6.3 ± 3.5 | 0.3 ± 0.5a | 0.9 ± 1.5a |
| Dyskinesia | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Motor fluctuation | 5.6 ± 2.9 | 0 ± 0a | 0.6 ± 1.2a |
| Off-state pain | 0.6 ± 1.4 | 0.3 ± 0.5 | 0.3 ± 0.5 |
(GPi) TEED, total electrical energy delivered by unilateral stimulation of the globus pallidus interna; LEDD, levodopa equivalent daily dose; n/a, not applicable; (STN) TEED, total electrical energy delivered by unilateral stimulation of the subthalamic nucleus; TEED, total electrical energy delivered; UPDRS, Unified Parkinson Disease Rating Scale.
a, bThe letters a and b indicate a significant difference (P < .05) between 2 time points (Friedman test and Wilcoxon post hoc test).
Values are presented as mean (SD).